BowRon
ActiveFinancials · financial year 2025, micro format
Annual accounts 2025 filed on 29-07-2026 at the NBB all 3 filings
2023 to 2025, 3 financial years
The operating result for 2025 is a profit of €9,248, after a loss of €3,363 in 2024. It is the highest result since 2023.
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
The higher the solvency, the better the company absorbs a setback.
A ratio above 1 means the short-term assets cover the short-term debts.
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Retail trade (NACE 47). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio and return on assets (ROA).
Comparable companies
These companies have the same main activity as BowRon: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €9,440 and €19,100, founded between 2015 and 2025.
| Company | Founded | Total assets | Equity | Gross margin | Net result | Financial year |
|---|---|---|---|---|---|---|
| BowRon Knokke-Heist | 2023 | €8,489 | €7,182 | €10,585 | €8,040 | 2025 |
| CAMILLE HUBY Etterbeek | 2023 | €18,562 | €14,443 | €10,507 | €7,758 | 2025 |
| NN Phar Eghezée | 2023 | €16,773 | €6,497 | €5,311 | €727 | 2025 |
| GRACE PARTNER Quaregnon | 2024 | €19,066 | €7,358 | €17,089 | €6,358 | 2025 |
| PHARMA SWITCH Merchtem | 2018 | €9,444 | €1,644 | €4,402 | €1,356 | 2025 |
| CROIXSSANCE PHARMA Zaventem | 2015 | €9,474 | -€15,015 | €5,783 | €1,861 | 2025 |
| FORMAPHARMA Andenne | 2025 | €17,739 | €14,461 | €16,079 | €12,461 | 2025 |
They were chosen from the 3,936 other active companies with that main activity and annual accounts from the past two years. All companies with this main activity
Companies with the same profile, two years later
Historical observationIn July 2024, 39,278 companies had the same profile as BowRon has now. Two years later, 1.8% had gone bankrupt and 95.9% were still going.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
That fits the bankruptcy probability of BowRon itself: 0.4% within 12 months.
Test of the method
The method was tested on the 497,445 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for BowRon. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | €403 | €1,210 | ▲ 200% |
| Other operating charges640/8 | €406 | €126 | €128 | ▲ 1.6% |
| Gross operating margin9900 | €1,173 | -€2,834 | €10,585 | - |
| Operating profit (loss)9901 | €766 | -€3,363 | €9,248 | - |
| Financial income75/76B | €0 | €5 | €1 | ▼ 76.4% |
| Recurring financial income75 | €0 | €5 | €1 | ▼ 76.4% |
| Financial charges65/66B | €75 | €53 | €48 | ▼ 8.9% |
| Recurring financial charges65 | €75 | €53 | €48 | ▼ 8.9% |
| Profit (loss) for the period before taxes9903 | €692 | -€3,411 | €9,201 | - |
| Income taxes67/77 | €138 | - | €1,161 | - |
| Profit (loss) for the period9904 | €553 | -€3,411 | €8,040 | - |
| Profit (loss) for the period to be appropriated9905 | €553 | -€3,411 | €8,040 | - |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Assets | ||||
| Total assets20/58 | €6,912 | €21,076 | €8,489 | ▼ 59.7% |
| Fixed assets21/28 | - | €3,226 | €2,016 | ▼ 37.5% |
| Tangible fixed assets22/27 | - | €3,226 | €2,016 | ▼ 37.5% |
| Plant, machinery and equipment23 | - | €3,226 | €2,016 | ▼ 37.5% |
| Current assets29/58 | €6,912 | €17,850 | €6,473 | ▼ 63.7% |
| Amounts receivable within one year40/41 | €850 | - | €4,145 | - |
| Trade receivables40 | €204 | - | - | - |
| Other amounts receivable41 | €645 | - | €4,145 | - |
| Cash at bank and in hand54/58 | €908 | €12,546 | €2,328 | ▼ 81.4% |
| Deferred charges and accrued income490/1 | €5,154 | €5,305 | - | - |
| Equity and liabilities | ||||
| Total equity and liabilities10/49 | €6,912 | €21,076 | €8,489 | ▼ 59.7% |
| Equity10/15 | €2,553 | -€858 | €7,182 | - |
| Contributions10/11 | €2,000 | €2,000 | €2,000 | = |
| Contributions outside capital11 | €2,000 | €2,000 | - | - |
| Other1109/19 | €2,000 | €2,000 | - | - |
| Profit (loss) carried forward14 | €553 | -€2,858 | €5,182 | - |
| Amounts payable17/49 | €4,359 | €21,933 | €1,307 | ▼ 94.0% |
| Amounts payable within one year42/48 | €4,359 | €21,933 | €1,307 | ▼ 94.0% |
| Trade debts44 | €1,627 | €148 | - | - |
| Suppliers440/4 | €1,627 | €148 | - | - |
| Taxes, remuneration and social security45 | €138 | €4,256 | €1,161 | ▼ 72.7% |
| Taxes450/3 | €138 | €4,256 | €1,161 | ▼ 72.7% |
| Other amounts payable47/48 | €2,594 | €17,529 | €145 | ▼ 99.2% |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Profit (loss) for the period9904 | €553 | -€3,411 | €8,040 | - |
| + Depreciation and write-downs630 | - | €403 | €1,210 | ▲ 200% |
| Operating cash flow (approximation) | €553 | -€3,008 | €9,250 | - |
| Investment in fixed assets (approximation) | - | - | €0 | - |
| Change in cash | - | €11,637 | -€10,218 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.